Conmed Corp (CNMD) FinancialsCNMDConmed Corp

Conmed Corp (CNMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is General Surgery, accounting for 58.9% of total sales, equivalent to $201.61M. Another important revenue stream is Orthopedic Surgery. Understanding this composition is critical for investors evaluating how CNMD navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Conmed Corp maintains a gross margin of 57.49%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.05%, while the net margin is 6.72%. These profitability ratios, combined with a Return on Equity (ROE) of 5.53%, provide a clear picture of how effectively CNMD converts its operational activities into shareholder value.

In the context of the broader market, CNMD competes directly with industry leaders such as BWAY and FRNM. With a market capitalization of $1.48B, it holds a significant position in the sector. When comparing efficiency, CNMD's gross margin of 57.49% stands against BWAY's 74.62% and FRNM's N/A. Such benchmarking helps identify whether Conmed Corp is trading at a premium or discount relative to its financial performance.

Conmed reported Q2 2026 revenue of $343.49 million, exceeding expectations and reflecting a 0.3% year-over-year increase. The adjusted gross margin improved to 59.5%, up 300 basis points year-over-year, enhancing profitability.